603896.SHG Zhejiang Shouxiangu Pharm Co
- Market cap
- CNY 2.75B
- P/E
- -
- P/B
- 1.18x
- ROE
- 2.3%
- Dividend yield
- 2.16%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603896.SHG undervalued?
Graham numberThe Graham number of Zhejiang Shouxiangu Pharm Co cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Shouxiangu Pharm Co fundamental analysis
No fundamental analysis for Zhejiang Shouxiangu Pharm Co yet.
Zhejiang Shouxiangu Pharm Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the breeding, cultivation, processing, and sale of Chinese medicinal herbs in China and internationally. The company offers ganoderma lucidum spore powder, dendrobium officinale, and saffron products, as well as health and ordinary food, agricultural and sideline products, personal and skincare, and traditional Chinese medicines under the Shouxiangu brand name. It is also involved in the…
Full company profileZhejiang Shouxiangu Pharm Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Shouxiangu Pharm Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 315M | 370M | 511M | 547M | 636M | 767M | 829M | 784M | 692M | 640M | 508M |
| Gross Profit | 267M | 319M | 439M | 461M | 530M | 641M | 700M | 649M | 558M | 504M | 379M |
| Operating Income | 71.0M | 90.8M | 110M | 128M | 159M | 207M | 281M | 255M | 175M | 124M | 66.8M |
| EBITDA | 128M | 127M | 150M | 167M | 209M | 261M | 349M | 346M | 254M | 219M | 84.0M |
| Net Income | 81.0M | 88.9M | 108M | 124M | 152M | 201M | 278M | 254M | 175M | 18.2M | 54.2M |
| EPS | 0.59 | 0.55 | 0.58 | 0.68 | 0.82 | 1.05 | 1.43 | 1.30 | 0.88 | 0.09 | 0.27 |
| Balance Sheet | |||||||||||
| Total Assets | 612M | 926M | 1.19B | 1.34B | 1.70B | 1.96B | 2.86B | 3.17B | 3.13B | 3.28B | 3.20B |
| Total Liabilities | 175M | 56.6M | 207M | 168M | 373M | 342M | 951M | 1.00B | 837M | 1.02B | 888M |
| Shareholders' Equity | 437M | 870M | 985M | 1.17B | 1.33B | 1.62B | 1.91B | 2.17B | 2.29B | 2.26B | 2.31B |
| Cash & Short-term Investments | 4.68M | 89.2M | 166M | 404M | 719M | 808M | 1.55B | 1.50B | 1.20B | 778M | 635M |
| Total Debt | 123M | - | 40.0M | 10.0M | 188M | 107M | 706M | 736M | 571M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 95.5M | 111M | 172M | 208M | 256M | 297M | 341M | 315M | 213M | 228M | - |
| Capital Expenditure | 40.3M | 31.4M | 233M | 91.5M | 65.0M | 162M | 183M | 415M | 507M | 273M | 178M |
| Free Cash Flow | 55.3M | 79.4M | -61.3M | 116M | 191M | 135M | 159M | -99.5M | -294M | -45.1M | -179M |
| Ratios | |||||||||||
| ROE | 18.5% | 10.2% | 10.9% | 10.6% | 11.4% | 12.4% | 14.6% | 11.7% | 7.6% | 0.8% | 2.3% |
| ROA | 13.2% | 9.6% | 9.0% | 9.2% | 8.9% | 10.2% | 9.7% | 8.0% | 5.6% | 0.6% | 1.7% |
| Net Profit Margin | 25.7% | 24.0% | 21.0% | 22.7% | 23.9% | 26.2% | 33.5% | 32.4% | 25.3% | 2.8% | 10.7% |
| Debt to Equity | 0.28x | - | 0.04x | 0.01x | 0.14x | 0.07x | 0.37x | 0.34x | 0.25x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Shouxiangu Pharm Co dividends
- Dividend yield
- 2.16%
- Forward dividend
- -
- Payout ratio
- 327.4%
- Ex-dividend date
- Jun 6, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 59.5M | 0.30 | 327.4% |
| 2024 | CNY 83.0M | 0.42 | 47.5% |
| 2023 | CNY 92.8M | 0.47 | 36.5% |
| 2022 | CNY 60.3M | 0.31 | 21.7% |
| 2021 | CNY 45.9M | 0.24 | 22.8% |
| 2020 | CNY 49.4M | 0.27 | 32.5% |
| 2019 | CNY 33.1M | 0.18 | 26.7% |
| 2018 | CNY 29.0M | 0.16 | 26.9% |
| 2017 | CNY 18.8M | 0.12 | 21.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 26, 2022.
Who owns Zhejiang Shouxiangu Pharm Co
- Insiders 46.17%
- Institutions 1.22%
- Public & others 52.62%
- Shares outstanding 198M
- Free float 112M
Zhejiang Shouxiangu Pharm Co company profile
- Company name
- Zhejiang Shouxiangu Pharm Co
- Ticker
- 603896.SHG
- ISIN
- CNE100002XJ4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Personal Care Products
- Employees
- 1,119
- Fiscal year end
- December
- Address
- No. 12, Huanglong Third Road, Jinhua, China, 321200
- Phone
- 86 40 0001 9058
- Website
- sxg1909.com
About Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the breeding, cultivation, processing, and sale of Chinese medicinal herbs in China and internationally. The company offers ganoderma lucidum spore powder, dendrobium officinale, and saffron products, as well as health and ordinary food, agricultural and sideline products, personal and skincare, and traditional Chinese medicines under the Shouxiangu brand name. It is also involved in the wholesale and retail; technology research and development; and real estate business. The company was founded in 1909 and is headquartered in Jinhua, China.
Zhejiang Shouxiangu Pharm Co management
7- Mr. Zhen-Yu LiGM & Director · born 1991
- Mr. Biao ZhuFinancial Director · born 1973
- Mr. Jing XuDeputy GM & Director · born 1985
- Mr. Rong Zhi LinVP & Director · born 1975
- Ms. Guofang LiuDeputy GM & Board Secretary · born 1976
- Mr. Han Bo WangDeputy General Manager · born 1977
- Yi ChenAccounting Supervisor